|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
PLX4032 is commonly used in the treatment of advanced melanoma patients with BRAF-V600E mutation.
|
31810919 |
2019 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib improves the management of advanced melanoma due to selective inhibition of the mutated BRAF V600E kinase.
|
29485438 |
2018 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Based on this analysis, we have adopted to screen patients with advanced melanoma with allele-specific V600E/K PCR and reflex negative cases for targeted NGS to maximize patient benefit.
|
29926184 |
2018 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To compare BRAF V600E status of primary melanoma and brain metastases to assess for discordance by cross-sectional study, and to evaluate clinical implications on BRAF inhibitor therapy.Brain metastases are common in patients with advanced melanoma.
|
29310328 |
2017 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutations other than V600E are reported.
|
29076950 |
2017 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dabrafenib, a type I inhibitor of BRAF interrupting RAF/MEK interaction, has been approved by FDA as a single agent or combined with MEK inhibitor trametinib for the treatment of patients with BRAF V600E mutation-positive advanced melanoma.
|
28536078 |
2017 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
VEM combined with S. typhimurium A1-R was significantly more effective than VEM alone or VEM combined with COB (P = 0.0216) which is currently first line therapy for advanced melanoma with a BRAF-V600E mutation.J.Cell.Biochem.118: 2314-2319, 2017.© 2017 Wiley Periodicals, Inc.
|
28106277 |
2017 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Treatment with trametinib, compared with chemotherapy, significantly reduced the risk of death and risk of disease progression in patients with BRAF V600E/K mutation-positive advanced melanoma or MM.
|
27172483 |
2016 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In total, 45 patients were enrolled; most (87 %) had advanced melanoma (94 % BRAF V600E).
|
26310975 |
2016 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
It might confer the metamorphic character of advanced melanoma for the patients who harbored BRAF(V600E) mutation.
|
25960652 |
2015 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
cfBRAF(V600E) quantification in plasma by ddPCR is useful as a follow-up to treatment response in patients with advanced melanoma.
|
25411185 |
2015 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
|
26058727 |
2015 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma show response to treatment with MAP kinase inhibitors, several sensitive methods have been developed to determine the V600 allele status of melanoma patients.
|
25037456 |
2014 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dabrafenib joins vemurafenib to confirm the superior clinical outcome of the BRAF inhibitors when compared with dacarbazine in patients with BRAF(V600E)-positive advanced melanoma.
|
24259661 |
2014 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib is a recently approved targeted therapy for advanced melanoma harboring the B-Raf valine-to-glutamate mutation at residue 600 (V600E).
|
24719071 |
2014 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.
|
23802768 |
2013 |
|
Advanced Melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
|
22742884 |
2012 |